Optimising Treatment of HF
Published: 21 April 2021
3m 2sPart 1 PART 1 – Introduction – Optimising Treatment of HF Martin R Cowie
10m 55sPart 2 PART 2 – A Review of Recent SGLT2 Inhibitor Data Giuseppe Rosano
11m 7sPart 3 PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor? Javed Butler
Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.
Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
- Heart Failure Specialists
- General Cardiologists
- Allied Health Professionals
More from this programme
PART 1 – Introduction – Optimising Treatment of HF
PART 2 – A Review of Recent SGLT2 Inhibitor Data
PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
PART 4 – Existing HF-REF: Augmenting the SOC
PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
Director of the Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.